Clinical bottom line
Anti-IL-33 therapies represent a promising but still investigational approach for managing refractory eosinophilic autoimmune diseases, a group characterized by persistent eosinophil-driven inflammation despite conventional treatments. Current evidence primarily extrapolates from related cytokine-targeting strategies, especially anti-IL-5 therapies, which have demonstrated clinical benefit in eosinophilic asthma and related disorders. IL-33 is a key upstream alarmin cytokine that activates type 2 immune responses, including eosinophil recruitment and activation, suggesting that IL-33 blockade could modulate disease pathways not fully addressed by existing biologics. However, robust clinical trial data specifically evaluating anti-IL-33 agents in eosinophilic autoimmune diseases remain limited. Clinicians should consider anti-IL-33 therapies as a putative option in refractory cases within clinical trial settings or specialized centers pending further validation.
What the evidence shows
Eosinophilic autoimmune diseases such as eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic chronic rhinosinusitis (ECRS), and eosinophilic nasal polyposis (ENP) share a common pathogenic axis involving type 2 cytokines including IL-4, IL-5, IL-13, and IL-33. IL-33 acts as an epithelial-derived alarmin that promotes type 2 inflammation by activating group 2 innate lymphoid cells (ILC2s), Th2 cells, and eosinophils. This upstream role positions IL-33 as a compelling therapeutic target (Elwany et al., 2026).
Anti-IL-5 therapies, such as mepolizumab and reslizumab, have demonstrated efficacy in reducing eosinophil counts and improving clinical outcomes in eosinophilic asthma and EGPA, providing a proof-of-concept for cytokine-targeted biologics in eosinophilic diseases (Byrne et al., 2022; Nagase et al., 2020). However, some patients remain refractory, suggesting that targeting upstream cytokines like IL-33 may address residual inflammation.
Recent reviews highlight that anti-IL-33 therapies could complement or surpass anti-IL-5 approaches by modulating multiple downstream pathways, including IL-5, IL-13, and eosinophil recruitment (Elwany et al., 2026). Early-phase clinical trials in eosinophilic airway diseases have shown safety and preliminary efficacy signals, but data specific to autoimmune phenotypes remain sparse.
In eosinophilic nasal polyposis, biologics targeting IL-4, IL-5, and IL-13 pathways have improved symptoms and polyp burden, yet refractory cases persist (Elwany et al., 2026). IL-33 blockade may offer additional benefit by dampening epithelial-immune cross-talk and tissue remodeling processes.
Caveats and uncertainty
The clinical utility of anti-IL-33 therapies in refractory eosinophilic autoimmune diseases is still hypothesis-generating. There is a paucity of large-scale randomized controlled trials directly assessing these agents in autoimmune contexts, limiting definitive conclusions on efficacy and safety.
Heterogeneity in disease phenotypes and overlap with allergic or non-autoimmune eosinophilic conditions complicates patient selection and interpretation of outcomes. Biomarkers to identify patients most likely to benefit from IL-33 blockade are not yet established.
Long-term safety data are lacking, and potential risks related to broad immune modulation warrant careful monitoring. Given the upstream position of IL-33 in immune activation, off-target effects or impaired host defense could emerge.
Comparative effectiveness versus established anti-IL-5 or anti-IL-4/13 therapies remains to be determined. Combination strategies targeting multiple cytokines may be required but increase complexity and cost.
How this may change practice
Pending further clinical validation, anti-IL-33 therapies could expand the therapeutic armamentarium for patients with refractory eosinophilic autoimmune diseases who do not respond adequately to current biologics. Their upstream mechanism may allow for broader modulation of type 2 inflammation and eosinophil activity.
Clinicians should remain aware of ongoing clinical trials investigating anti-IL-33 agents and consider referral of eligible patients to specialized centers. Integration of IL-33 blockade into treatment algorithms will require evidence on comparative efficacy, safety, and biomarker-guided patient selection.
In the near term, anti-IL-33 therapies may complement existing anti-IL-5 or anti-IL-4/13 biologics, particularly in complex or overlapping eosinophilic phenotypes. Multidisciplinary collaboration and longitudinal monitoring will be essential to optimize outcomes and detect adverse effects.